Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency

Last updated: December 11, 2020
Sponsor: Novartis
Overall Status: Completed

Phase

3

Condition

Renal Failure

Diabetes Prevention

Nephropathy

Treatment

N/A

Clinical Study ID

NCT00646542
CLAF237A23137
  • Ages 18-85
  • All Genders

Study Summary

This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) when used in patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal insufficiency.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • History T2DM
  • Moderate or Severe Renal Impairment

Exclusion

Exclusion Criteria:

  • Glucose > 270 mg/dL (>15 mmol/L) Other protocol-defined inclusion/exclusion criteria may apply.

Study Design

Total Participants: 525
Study Start date:
March 01, 2005
Estimated Completion Date:

Connect with a study center

  • Buenos Aires,
    Argentina

    Site Not Available

  • Heidelberg Heights,
    Australia

    Site Not Available

  • Winnipeg,
    Canada

    Site Not Available

  • Cartago,
    Costa Rica

    Site Not Available

  • Tampere,
    Finland

    Site Not Available

  • Angers,
    France

    Site Not Available

  • Dormagen,
    Germany

    Site Not Available

  • Chennai,
    India

    Site Not Available

  • Oslo,
    Norway

    Site Not Available

  • Saint Petersburg,
    Russian Federation

    Site Not Available

  • Alicante,
    Spain

    Site Not Available

  • Lund,
    Sweden

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.